Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunovant Inc IMVT

Healthcare Biotechnology
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is... see more

Recent & Breaking News (NDAQ:IMVT)

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

GlobeNewswire November 7, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

GlobeNewswire October 29, 2024

Roivant Provides Update on Graves' Disease Development Program

GlobeNewswire September 9, 2024

Immunovant Provides Update on Graves' Disease Development Program

GlobeNewswire September 9, 2024

Immunovant to Host Graves' Disease Program Update on September 9, 2024

GlobeNewswire September 5, 2024

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

GlobeNewswire August 6, 2024

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

GlobeNewswire May 29, 2024

Immunovant Awarded U.S. Patent for IMVT-1402

GlobeNewswire March 12, 2024

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

GlobeNewswire February 12, 2024

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

GlobeNewswire December 20, 2023

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

GlobeNewswire December 20, 2023

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

GlobeNewswire November 28, 2023

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

GlobeNewswire November 28, 2023

Immunovant to Present at Upcoming Investor Conferences

GlobeNewswire November 13, 2023

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

GlobeNewswire November 9, 2023

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire October 2, 2023

Immunovant Announces Pricing of $450 Million Common Stock Financing

GlobeNewswire September 27, 2023

Immunovant Announces Proposed Offering of $300 Million of Common Stock

GlobeNewswire September 26, 2023

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

GlobeNewswire September 26, 2023